Patent applications: 143
Patents issued: 68
Filed after FDA approval: 99%
Duration of patent protection: 41.2 years
Fold-more patents filed in U.S. vs Europe: 2.2
Fold-more patents filed in U.S. vs Japan: 2.8
PRICING
Price increase 2014-19: -55%
SPENDING
Medicare spending per beneficiary: $55,527
Total Medicare spending (2018): $1,208,097,769
MARKET
On the U.S. market since: 1996
Generic / biosim approved: 2015
Generic / biosim on the market: 2015
DRUG INFORMATION
Company: Teva
Condition(s) Treated: Multiple Sclerosis
Drug Type: Small Molecule
Notes
Patent data as of May 2020
Data on pricing changes from 2014-19 were obtained from IQVIA monthly NSP prices during that period. These represent total spending on prescription medicines from wholesaler transactions and include all on-invoice discounts, but no off-invoice discounts or rebates
Data on prices and spending for Medicare and Medicaid were obtained from the CMS ‘Drug Spending Database’ and reflect data from 2014-2018
Medicare price increases are based on average annual changes in the price per beneficiary over the period 2014-2018 and spending per beneficiary is for 2018
Medicaid price increases are based on average changes in the price per claim over the period 2014-2018
Partner with us now to build a more just and equitable medicine system for all.